Jeri Forster
Concepts (528)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 89 | 2026 | 1675 | 7.820 |
Why?
| | Brain Injuries, Traumatic | 20 | 2026 | 462 | 2.960 |
Why?
| | Suicidal Ideation | 24 | 2025 | 590 | 2.860 |
Why?
| | Suicide | 18 | 2026 | 737 | 2.560 |
Why?
| | Brain Concussion | 19 | 2025 | 661 | 1.980 |
Why?
| | Military Personnel | 14 | 2025 | 749 | 1.630 |
Why?
| | Brain Injuries | 10 | 2022 | 508 | 1.580 |
Why?
| | United States Department of Veterans Affairs | 28 | 2026 | 793 | 1.530 |
Why?
| | Sleep Initiation and Maintenance Disorders | 9 | 2025 | 198 | 1.520 |
Why?
| | Sex Offenses | 7 | 2023 | 199 | 1.500 |
Why?
| | Stress Disorders, Post-Traumatic | 19 | 2026 | 902 | 1.480 |
Why?
| | Suicide, Attempted | 11 | 2025 | 430 | 1.290 |
Why?
| | Occupational Therapy | 8 | 2026 | 110 | 1.210 |
Why?
| | Arthroplasty, Replacement, Knee | 10 | 2026 | 383 | 1.180 |
Why?
| | Mental Disorders | 12 | 2026 | 1188 | 1.140 |
Why?
| | United States | 72 | 2026 | 16313 | 1.090 |
Why?
| | Activities of Daily Living | 9 | 2025 | 449 | 1.010 |
Why?
| | Post-Concussion Syndrome | 5 | 2024 | 185 | 0.910 |
Why?
| | Middle Aged | 88 | 2026 | 36819 | 0.890 |
Why?
| | Health Services Accessibility | 8 | 2026 | 1122 | 0.880 |
Why?
| | Self-Injurious Behavior | 4 | 2020 | 143 | 0.870 |
Why?
| | Home Care Services | 8 | 2024 | 291 | 0.860 |
Why?
| | Physical Therapy Modalities | 10 | 2024 | 346 | 0.840 |
Why?
| | Female | 124 | 2026 | 80054 | 0.840 |
Why?
| | Male | 121 | 2026 | 73928 | 0.820 |
Why?
| | Humans | 169 | 2026 | 147265 | 0.820 |
Why?
| | Arthroplasty, Replacement, Hip | 5 | 2025 | 187 | 0.810 |
Why?
| | Aged | 59 | 2026 | 26509 | 0.770 |
Why?
| | Adult | 81 | 2026 | 41404 | 0.770 |
Why?
| | Skilled Nursing Facilities | 6 | 2023 | 152 | 0.770 |
Why?
| | Aftercare | 2 | 2021 | 225 | 0.730 |
Why?
| | Patient Discharge | 13 | 2025 | 1002 | 0.730 |
Why?
| | Psychometrics | 7 | 2024 | 739 | 0.700 |
Why?
| | Sexual Harassment | 3 | 2016 | 29 | 0.690 |
Why?
| | Sleep Wake Disorders | 5 | 2026 | 315 | 0.650 |
Why?
| | Multimorbidity | 3 | 2026 | 66 | 0.630 |
Why?
| | Embolism, Fat | 1 | 2020 | 11 | 0.630 |
Why?
| | Resistance Training | 4 | 2024 | 186 | 0.630 |
Why?
| | Social Support | 1 | 2024 | 654 | 0.590 |
Why?
| | Osteoarthritis, Knee | 4 | 2026 | 284 | 0.580 |
Why?
| | Referral and Consultation | 3 | 2025 | 886 | 0.580 |
Why?
| | Hospitalization | 11 | 2025 | 2495 | 0.570 |
Why?
| | Muscle Strength | 8 | 2026 | 334 | 0.520 |
Why?
| | Recovery of Function | 9 | 2026 | 724 | 0.520 |
Why?
| | Cross-Sectional Studies | 19 | 2025 | 6003 | 0.500 |
Why?
| | Edema | 3 | 2026 | 128 | 0.490 |
Why?
| | Retrospective Studies | 35 | 2026 | 17561 | 0.490 |
Why?
| | Exercise Therapy | 7 | 2025 | 488 | 0.480 |
Why?
| | Multiple Trauma | 3 | 2026 | 121 | 0.470 |
Why?
| | Firearms | 1 | 2022 | 438 | 0.460 |
Why?
| | Death | 1 | 2016 | 132 | 0.460 |
Why?
| | Sleep Apnea, Obstructive | 3 | 2024 | 303 | 0.450 |
Why?
| | Multiple Sclerosis | 4 | 2024 | 491 | 0.450 |
Why?
| | Patient Dropouts | 2 | 2015 | 67 | 0.440 |
Why?
| | Neuropsychological Tests | 4 | 2019 | 1145 | 0.440 |
Why?
| | Risk Factors | 18 | 2025 | 11016 | 0.440 |
Why?
| | Telerehabilitation | 2 | 2026 | 50 | 0.420 |
Why?
| | Osteoarthritis, Hip | 2 | 2025 | 49 | 0.420 |
Why?
| | Executive Function | 3 | 2017 | 472 | 0.400 |
Why?
| | Gait | 3 | 2025 | 317 | 0.390 |
Why?
| | Health Personnel | 4 | 2024 | 759 | 0.390 |
Why?
| | Walking Speed | 3 | 2024 | 53 | 0.380 |
Why?
| | Sex Factors | 8 | 2026 | 2133 | 0.380 |
Why?
| | Knee Joint | 3 | 2026 | 439 | 0.380 |
Why?
| | Fear | 1 | 2016 | 373 | 0.380 |
Why?
| | Veterans Health | 6 | 2023 | 191 | 0.370 |
Why?
| | Biofeedback, Psychology | 2 | 2025 | 35 | 0.360 |
Why?
| | Burnout, Professional | 3 | 2024 | 490 | 0.360 |
Why?
| | Biometry | 1 | 2011 | 66 | 0.340 |
Why?
| | Young Adult | 17 | 2025 | 14437 | 0.340 |
Why?
| | Decision Support Techniques | 2 | 2026 | 480 | 0.330 |
Why?
| | Randomized Controlled Trials as Topic | 9 | 2026 | 1776 | 0.330 |
Why?
| | Probability | 1 | 2011 | 309 | 0.320 |
Why?
| | Aged, 80 and over | 16 | 2025 | 8429 | 0.310 |
Why?
| | Physical and Rehabilitation Medicine | 2 | 2021 | 30 | 0.300 |
Why?
| | Feasibility Studies | 9 | 2026 | 1145 | 0.300 |
Why?
| | Patient Readmission | 4 | 2024 | 777 | 0.300 |
Why?
| | Walking | 4 | 2024 | 548 | 0.300 |
Why?
| | Pilot Projects | 9 | 2026 | 1912 | 0.280 |
Why?
| | Electric Impedance | 2 | 2019 | 108 | 0.280 |
Why?
| | Models, Statistical | 2 | 2015 | 677 | 0.270 |
Why?
| | Anti-HIV Agents | 3 | 2015 | 919 | 0.270 |
Why?
| | Exercise | 4 | 2021 | 2210 | 0.270 |
Why?
| | Depression | 7 | 2024 | 1599 | 0.260 |
Why?
| | Risk | 6 | 2023 | 927 | 0.260 |
Why?
| | Decision Support Systems, Clinical | 2 | 2026 | 278 | 0.260 |
Why?
| | Healthcare Disparities | 2 | 2025 | 741 | 0.260 |
Why?
| | Longitudinal Studies | 9 | 2025 | 3029 | 0.260 |
Why?
| | Walk Test | 2 | 2024 | 82 | 0.260 |
Why?
| | Factor Analysis, Statistical | 5 | 2024 | 296 | 0.260 |
Why?
| | Prospective Studies | 8 | 2025 | 8165 | 0.260 |
Why?
| | September 11 Terrorist Attacks | 2 | 2025 | 31 | 0.250 |
Why?
| | Chronic Pain | 2 | 2024 | 301 | 0.250 |
Why?
| | Lower Extremity | 3 | 2024 | 452 | 0.250 |
Why?
| | Patient Compliance | 4 | 2024 | 590 | 0.250 |
Why?
| | Occupational Diseases | 2 | 2019 | 165 | 0.240 |
Why?
| | Anxiety | 4 | 2024 | 1149 | 0.240 |
Why?
| | Criminal Law | 1 | 2026 | 31 | 0.230 |
Why?
| | Criminals | 1 | 2026 | 34 | 0.230 |
Why?
| | Inpatients | 5 | 2026 | 556 | 0.230 |
Why?
| | Acceptance and Commitment Therapy | 1 | 2026 | 36 | 0.230 |
Why?
| | Subacute Care | 3 | 2021 | 84 | 0.230 |
Why?
| | Disability Evaluation | 2 | 2020 | 312 | 0.220 |
Why?
| | Morals | 1 | 2026 | 85 | 0.220 |
Why?
| | Postural Balance | 2 | 2018 | 254 | 0.220 |
Why?
| | Comorbidity | 7 | 2025 | 1672 | 0.210 |
Why?
| | HIV Infections | 7 | 2015 | 3235 | 0.210 |
Why?
| | Social Participation | 1 | 2025 | 29 | 0.210 |
Why?
| | Mobile Applications | 2 | 2025 | 199 | 0.210 |
Why?
| | Art Therapy | 1 | 2024 | 23 | 0.210 |
Why?
| | Risk Assessment | 9 | 2026 | 3784 | 0.210 |
Why?
| | Enterobacter cloacae | 1 | 2024 | 5 | 0.210 |
Why?
| | Wearable Electronic Devices | 1 | 2025 | 75 | 0.210 |
Why?
| | Adolescent | 14 | 2024 | 22814 | 0.210 |
Why?
| | Age Factors | 4 | 2026 | 3370 | 0.200 |
Why?
| | Smartphone | 1 | 2025 | 107 | 0.200 |
Why?
| | Decision Making | 3 | 2024 | 993 | 0.200 |
Why?
| | Patient Health Questionnaire | 1 | 2024 | 44 | 0.200 |
Why?
| | Seasonal Affective Disorder | 1 | 2023 | 9 | 0.200 |
Why?
| | Gastrointestinal Microbiome | 2 | 2023 | 773 | 0.200 |
Why?
| | Self Report | 6 | 2019 | 885 | 0.200 |
Why?
| | Medicare | 5 | 2021 | 915 | 0.200 |
Why?
| | Enterobacteriaceae Infections | 1 | 2024 | 43 | 0.200 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2024 | 90 | 0.200 |
Why?
| | Attitude of Health Personnel | 2 | 2026 | 1219 | 0.190 |
Why?
| | Luteinizing Hormone | 2 | 2023 | 207 | 0.190 |
Why?
| | Frail Elderly | 1 | 2024 | 136 | 0.190 |
Why?
| | Outpatients | 4 | 2025 | 450 | 0.180 |
Why?
| | Iraq War, 2003-2011 | 5 | 2024 | 173 | 0.180 |
Why?
| | Mass Screening | 2 | 2026 | 1375 | 0.180 |
Why?
| | Antidepressive Agents | 1 | 2024 | 245 | 0.180 |
Why?
| | Health Services Needs and Demand | 2 | 2021 | 289 | 0.180 |
Why?
| | Case-Control Studies | 6 | 2022 | 3660 | 0.180 |
Why?
| | Geriatric Assessment | 2 | 2024 | 240 | 0.180 |
Why?
| | Residence Characteristics | 1 | 2025 | 387 | 0.170 |
Why?
| | Psychological Trauma | 1 | 2022 | 58 | 0.170 |
Why?
| | Range of Motion, Articular | 4 | 2026 | 440 | 0.170 |
Why?
| | Nutritional Status | 1 | 2024 | 349 | 0.170 |
Why?
| | Nerve Compression Syndromes | 1 | 2021 | 22 | 0.170 |
Why?
| | Ownership | 1 | 2022 | 116 | 0.170 |
Why?
| | Prevalence | 5 | 2021 | 2888 | 0.170 |
Why?
| | Postoperative Complications | 3 | 2026 | 3022 | 0.170 |
Why?
| | Cognition Disorders | 1 | 2025 | 551 | 0.170 |
Why?
| | Cross Infection | 1 | 2024 | 261 | 0.170 |
Why?
| | Reproducibility of Results | 5 | 2022 | 3445 | 0.170 |
Why?
| | Radiculopathy | 1 | 2021 | 38 | 0.170 |
Why?
| | Psychiatric Status Rating Scales | 3 | 2018 | 537 | 0.170 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2024 | 1430 | 0.170 |
Why?
| | Guideline Adherence | 1 | 2025 | 590 | 0.160 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2016 | 442 | 0.160 |
Why?
| | Stroke Rehabilitation | 1 | 2021 | 44 | 0.160 |
Why?
| | Physical Abuse | 1 | 2021 | 41 | 0.160 |
Why?
| | Women | 1 | 2021 | 47 | 0.160 |
Why?
| | Glasgow Outcome Scale | 1 | 2020 | 14 | 0.160 |
Why?
| | Frailty | 1 | 2024 | 206 | 0.160 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2021 | 134 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2025 | 625 | 0.160 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2021 | 96 | 0.150 |
Why?
| | Survivors | 2 | 2021 | 528 | 0.150 |
Why?
| | Single-Blind Method | 4 | 2024 | 319 | 0.150 |
Why?
| | Mobility Limitation | 1 | 2020 | 67 | 0.150 |
Why?
| | Value of Life | 2 | 2016 | 19 | 0.150 |
Why?
| | Internship and Residency | 2 | 2021 | 1279 | 0.150 |
Why?
| | Arthroplasty, Replacement | 1 | 2020 | 47 | 0.150 |
Why?
| | Students, Health Occupations | 1 | 2020 | 37 | 0.150 |
Why?
| | Glasgow Coma Scale | 1 | 2020 | 218 | 0.150 |
Why?
| | Substance-Related Disorders | 2 | 2023 | 1112 | 0.150 |
Why?
| | Interviews as Topic | 4 | 2026 | 931 | 0.140 |
Why?
| | Myofascial Pain Syndromes | 1 | 2019 | 12 | 0.140 |
Why?
| | Competency-Based Education | 1 | 2020 | 82 | 0.140 |
Why?
| | Medicine | 1 | 2021 | 126 | 0.140 |
Why?
| | Transitional Care | 1 | 2019 | 46 | 0.140 |
Why?
| | Electromyography | 1 | 2021 | 419 | 0.140 |
Why?
| | Speech Discrimination Tests | 1 | 2018 | 6 | 0.140 |
Why?
| | Pelvic Pain | 1 | 2019 | 42 | 0.140 |
Why?
| | Health Services for the Aged | 1 | 2019 | 73 | 0.140 |
Why?
| | Sense of Coherence | 1 | 2018 | 12 | 0.140 |
Why?
| | Drug Overdose | 1 | 2023 | 381 | 0.130 |
Why?
| | Mental Health Services | 4 | 2024 | 478 | 0.130 |
Why?
| | Physical Therapists | 1 | 2019 | 68 | 0.130 |
Why?
| | Hope | 1 | 2018 | 31 | 0.130 |
Why?
| | Professional Role | 1 | 2019 | 171 | 0.130 |
Why?
| | Afghan Campaign 2001- | 4 | 2022 | 194 | 0.130 |
Why?
| | Eye Movements | 1 | 2018 | 94 | 0.130 |
Why?
| | Combat Disorders | 1 | 2017 | 42 | 0.130 |
Why?
| | Drug Packaging | 1 | 2017 | 41 | 0.130 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1342 | 0.130 |
Why?
| | Speech Perception | 1 | 2018 | 91 | 0.120 |
Why?
| | Personality Assessment | 1 | 2017 | 79 | 0.120 |
Why?
| | Prefrontal Cortex | 2 | 2017 | 342 | 0.120 |
Why?
| | Depressive Disorder | 2 | 2018 | 379 | 0.120 |
Why?
| | Joint Instability | 1 | 2019 | 187 | 0.120 |
Why?
| | Educational Measurement | 1 | 2020 | 332 | 0.120 |
Why?
| | War Exposure | 1 | 2016 | 15 | 0.120 |
Why?
| | Pain Measurement | 1 | 2019 | 569 | 0.120 |
Why?
| | Visual Perception | 1 | 2018 | 184 | 0.120 |
Why?
| | Nelfinavir | 1 | 2016 | 8 | 0.120 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1996 | 38 | 0.120 |
Why?
| | Microbiota | 1 | 2023 | 736 | 0.120 |
Why?
| | Vaccines, DNA | 2 | 2008 | 32 | 0.120 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2974 | 0.120 |
Why?
| | Lopinavir | 1 | 2016 | 31 | 0.120 |
Why?
| | Hypertension, Portal | 1 | 1996 | 67 | 0.120 |
Why?
| | Atazanavir Sulfate | 1 | 2016 | 42 | 0.120 |
Why?
| | Patient Safety | 1 | 2020 | 356 | 0.120 |
Why?
| | Parkinson Disease | 1 | 2022 | 613 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 25 | 0.120 |
Why?
| | AIDS Vaccines | 2 | 2008 | 53 | 0.110 |
Why?
| | Attitude to Death | 1 | 2016 | 76 | 0.110 |
Why?
| | HIV-1 | 3 | 2008 | 917 | 0.110 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2016 | 86 | 0.110 |
Why?
| | HIV Protease Inhibitors | 1 | 2016 | 70 | 0.110 |
Why?
| | Ritonavir | 1 | 2016 | 76 | 0.110 |
Why?
| | Gene Dosage | 1 | 2016 | 145 | 0.110 |
Why?
| | Child | 8 | 2024 | 22960 | 0.110 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 76 | 0.110 |
Why?
| | Medical Records | 1 | 2016 | 191 | 0.110 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2008 | 180 | 0.110 |
Why?
| | Actigraphy | 1 | 2016 | 148 | 0.110 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 81 | 0.110 |
Why?
| | Medication Errors | 1 | 2015 | 85 | 0.110 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2008 | 174 | 0.110 |
Why?
| | Exome | 1 | 2016 | 233 | 0.110 |
Why?
| | Hearing Loss | 1 | 2018 | 252 | 0.110 |
Why?
| | Warfare | 1 | 2015 | 100 | 0.110 |
Why?
| | Clinical Competence | 2 | 2020 | 1260 | 0.100 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 116 | 0.100 |
Why?
| | Videotape Recording | 1 | 1994 | 37 | 0.100 |
Why?
| | Surveys and Questionnaires | 6 | 2018 | 6161 | 0.100 |
Why?
| | Thalamus | 1 | 2015 | 132 | 0.100 |
Why?
| | Ozone | 3 | 2000 | 116 | 0.100 |
Why?
| | Risk-Taking | 2 | 2017 | 325 | 0.100 |
Why?
| | Dizziness | 3 | 2019 | 101 | 0.100 |
Why?
| | Complementary Therapies | 1 | 2014 | 96 | 0.100 |
Why?
| | Ambulatory Surgical Procedures | 1 | 1994 | 79 | 0.100 |
Why?
| | Cohort Studies | 6 | 2021 | 6095 | 0.100 |
Why?
| | Cerebellum | 1 | 2015 | 227 | 0.100 |
Why?
| | Hypertension | 1 | 2022 | 1280 | 0.100 |
Why?
| | Violence | 1 | 2017 | 282 | 0.100 |
Why?
| | Liver Diseases | 1 | 1996 | 307 | 0.100 |
Why?
| | Injury Severity Score | 1 | 2015 | 602 | 0.100 |
Why?
| | Iraq | 2 | 2024 | 67 | 0.100 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2015 | 194 | 0.100 |
Why?
| | Medication Adherence | 1 | 2017 | 540 | 0.090 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 267 | 0.090 |
Why?
| | Afghanistan | 2 | 2024 | 97 | 0.090 |
Why?
| | Pandemics | 1 | 2021 | 1719 | 0.090 |
Why?
| | Thinness | 1 | 2013 | 100 | 0.090 |
Why?
| | Qualitative Research | 3 | 2026 | 1732 | 0.090 |
Why?
| | Athletic Injuries | 1 | 2019 | 576 | 0.090 |
Why?
| | Emotions | 1 | 2018 | 583 | 0.090 |
Why?
| | Fatigue | 3 | 2019 | 367 | 0.090 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 1167 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2015 | 400 | 0.090 |
Why?
| | Time Factors | 5 | 2021 | 7173 | 0.080 |
Why?
| | Preoperative Care | 1 | 1994 | 381 | 0.080 |
Why?
| | Biomechanical Phenomena | 2 | 2025 | 873 | 0.080 |
Why?
| | Treatment Outcome | 6 | 2025 | 11944 | 0.080 |
Why?
| | Quality Improvement | 1 | 2020 | 1321 | 0.080 |
Why?
| | Algorithms | 2 | 2026 | 1868 | 0.080 |
Why?
| | Quadriceps Muscle | 2 | 2024 | 120 | 0.080 |
Why?
| | Attitude to Health | 1 | 1994 | 429 | 0.080 |
Why?
| | Patient Reported Outcome Measures | 2 | 2026 | 506 | 0.080 |
Why?
| | Tertiary Care Centers | 2 | 2024 | 196 | 0.080 |
Why?
| | Hospitals, Veterans | 3 | 2019 | 259 | 0.080 |
Why?
| | Mental Health | 3 | 2023 | 810 | 0.080 |
Why?
| | HIV | 1 | 2011 | 251 | 0.080 |
Why?
| | Bayes Theorem | 2 | 2022 | 428 | 0.080 |
Why?
| | Glucose | 1 | 2015 | 1051 | 0.080 |
Why?
| | Double-Blind Method | 3 | 2025 | 2080 | 0.080 |
Why?
| | Receptors, CXCR4 | 2 | 2007 | 91 | 0.080 |
Why?
| | Epilepsy | 1 | 2014 | 399 | 0.070 |
Why?
| | Cross-Over Studies | 2 | 2025 | 615 | 0.070 |
Why?
| | Wounds and Injuries | 1 | 2018 | 977 | 0.070 |
Why?
| | Analysis of Variance | 3 | 2019 | 1300 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 1994 | 781 | 0.070 |
Why?
| | Patient Satisfaction | 2 | 2026 | 718 | 0.070 |
Why?
| | Adipose Tissue | 1 | 2013 | 644 | 0.070 |
Why?
| | Oxidants, Photochemical | 2 | 1999 | 8 | 0.070 |
Why?
| | Cognition | 3 | 2023 | 1286 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2025 | 1344 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 3980 | 0.070 |
Why?
| | Length of Stay | 1 | 2014 | 1371 | 0.070 |
Why?
| | Seasons | 3 | 2000 | 540 | 0.070 |
Why?
| | Colorado | 4 | 2023 | 4591 | 0.070 |
Why?
| | RNA, Viral | 1 | 2011 | 695 | 0.060 |
Why?
| | Incidence | 2 | 2025 | 2954 | 0.060 |
Why?
| | Trauma Severity Indices | 2 | 2019 | 117 | 0.060 |
Why?
| | Interferon-gamma | 2 | 2008 | 786 | 0.060 |
Why?
| | alpha-Defensins | 1 | 2006 | 11 | 0.060 |
Why?
| | Creutzfeldt-Jakob Syndrome | 1 | 2006 | 19 | 0.060 |
Why?
| | Prion Diseases | 1 | 2006 | 25 | 0.060 |
Why?
| | Parents | 1 | 2015 | 1428 | 0.060 |
Why?
| | Granulocytes | 1 | 2006 | 83 | 0.060 |
Why?
| | Wasting Disease, Chronic | 1 | 2006 | 46 | 0.060 |
Why?
| | Lymphoid Tissue | 1 | 2006 | 81 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2015 | 1162 | 0.060 |
Why?
| | Germany | 2 | 2024 | 140 | 0.060 |
Why?
| | Interleukin-18 | 1 | 2007 | 234 | 0.060 |
Why?
| | Mutation | 2 | 2016 | 4130 | 0.060 |
Why?
| | Anti-Retroviral Agents | 1 | 2007 | 251 | 0.060 |
Why?
| | Models, Psychological | 2 | 2018 | 295 | 0.060 |
Why?
| | Follicle Stimulating Hormone | 2 | 2023 | 266 | 0.050 |
Why?
| | Preoperative Period | 1 | 2025 | 150 | 0.050 |
Why?
| | Quality of Life | 3 | 2024 | 3243 | 0.050 |
Why?
| | Insulin Resistance | 1 | 2013 | 1252 | 0.050 |
Why?
| | Exercise Test | 2 | 2019 | 636 | 0.050 |
Why?
| | Sex Distribution | 2 | 2023 | 390 | 0.050 |
Why?
| | Accelerometry | 1 | 2025 | 123 | 0.050 |
Why?
| | Infant, Newborn | 4 | 2024 | 6543 | 0.050 |
Why?
| | Treatment Adherence and Compliance | 1 | 2024 | 27 | 0.050 |
Why?
| | Rehabilitation Centers | 1 | 2024 | 39 | 0.050 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 39 | 0.050 |
Why?
| | Hand Strength | 1 | 2024 | 145 | 0.050 |
Why?
| | Phototherapy | 1 | 2023 | 50 | 0.050 |
Why?
| | Epidemiological Monitoring | 1 | 2024 | 70 | 0.050 |
Why?
| | Triamcinolone Acetonide | 1 | 2023 | 20 | 0.050 |
Why?
| | Crisis Intervention | 1 | 2023 | 37 | 0.050 |
Why?
| | Calorimetry, Indirect | 1 | 2003 | 72 | 0.050 |
Why?
| | Neuroimaging | 2 | 2017 | 309 | 0.050 |
Why?
| | Follow-Up Studies | 4 | 2018 | 5477 | 0.050 |
Why?
| | Global Burden of Disease | 1 | 2023 | 25 | 0.050 |
Why?
| | Death Certificates | 1 | 2023 | 32 | 0.050 |
Why?
| | Conserved Sequence | 1 | 2003 | 244 | 0.050 |
Why?
| | Emergency Service, Hospital | 1 | 2015 | 2416 | 0.050 |
Why?
| | Hip Joint | 1 | 2024 | 173 | 0.050 |
Why?
| | Transportation of Patients | 1 | 2023 | 65 | 0.050 |
Why?
| | Movement | 1 | 2025 | 293 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1046 | 0.050 |
Why?
| | Mood Disorders | 1 | 2023 | 145 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2024 | 513 | 0.040 |
Why?
| | Ohio | 1 | 2022 | 146 | 0.040 |
Why?
| | Personnel Turnover | 1 | 2022 | 40 | 0.040 |
Why?
| | Accidental Falls | 1 | 2024 | 231 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2022 | 173 | 0.040 |
Why?
| | Bacteremia | 1 | 2024 | 222 | 0.040 |
Why?
| | Policy | 1 | 2022 | 149 | 0.040 |
Why?
| | Needs Assessment | 1 | 2024 | 409 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 933 | 0.040 |
Why?
| | Infant | 3 | 2024 | 10195 | 0.040 |
Why?
| | Headache | 1 | 2022 | 151 | 0.040 |
Why?
| | Cause of Death | 1 | 2023 | 475 | 0.040 |
Why?
| | Postoperative Period | 1 | 2021 | 351 | 0.040 |
Why?
| | Cost of Illness | 1 | 2023 | 327 | 0.040 |
Why?
| | Testosterone | 2 | 2023 | 417 | 0.040 |
Why?
| | Anxiety Disorders | 1 | 2023 | 376 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 487 | 0.040 |
Why?
| | Administrative Claims, Healthcare | 1 | 2020 | 28 | 0.040 |
Why?
| | Cardiovascular Deconditioning | 1 | 2019 | 5 | 0.040 |
Why?
| | Hyperacusis | 1 | 2019 | 9 | 0.040 |
Why?
| | Photophobia | 1 | 2019 | 13 | 0.040 |
Why?
| | Job Satisfaction | 1 | 2022 | 238 | 0.040 |
Why?
| | Internet | 1 | 2024 | 696 | 0.040 |
Why?
| | Education, Graduate | 1 | 2020 | 35 | 0.040 |
Why?
| | Ribonucleases | 1 | 1999 | 48 | 0.040 |
Why?
| | Hypesthesia | 1 | 2019 | 21 | 0.040 |
Why?
| | Obesity | 1 | 2013 | 3144 | 0.040 |
Why?
| | Cervical Vertebrae | 1 | 2021 | 170 | 0.040 |
Why?
| | Fee-for-Service Plans | 1 | 2020 | 99 | 0.040 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2019 | 12 | 0.040 |
Why?
| | Pain | 1 | 2024 | 794 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2000 | 269 | 0.040 |
Why?
| | Rehabilitation | 1 | 2019 | 20 | 0.040 |
Why?
| | Inhalation Exposure | 1 | 1999 | 103 | 0.040 |
Why?
| | Independent Living | 1 | 2020 | 114 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 2627 | 0.030 |
Why?
| | Health Education | 1 | 2001 | 346 | 0.030 |
Why?
| | Organizational Culture | 1 | 2020 | 162 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2019 | 329 | 0.030 |
Why?
| | Ethanol | 1 | 2023 | 634 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2026 | 1598 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2020 | 512 | 0.030 |
Why?
| | Sleep | 2 | 2022 | 895 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2000 | 247 | 0.030 |
Why?
| | Fetal Blood | 1 | 2000 | 327 | 0.030 |
Why?
| | Rhinitis | 1 | 1999 | 169 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2001 | 441 | 0.030 |
Why?
| | Disease Progression | 2 | 2016 | 2892 | 0.030 |
Why?
| | Reference Values | 1 | 2019 | 798 | 0.030 |
Why?
| | Regression Analysis | 2 | 2003 | 1002 | 0.030 |
Why?
| | Patient Admission | 1 | 2019 | 220 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2003 | 931 | 0.030 |
Why?
| | Feedback | 1 | 2017 | 181 | 0.030 |
Why?
| | Self Care | 1 | 2020 | 395 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 290 | 0.030 |
Why?
| | Adolescent Behavior | 1 | 2001 | 496 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2023 | 950 | 0.030 |
Why?
| | Public Health | 1 | 2021 | 576 | 0.030 |
Why?
| | Emergency Medical Services | 1 | 2023 | 691 | 0.030 |
Why?
| | Prognosis | 2 | 2016 | 4384 | 0.030 |
Why?
| | Organ Size | 1 | 2017 | 465 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 975 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2016 | 34 | 0.030 |
Why?
| | Child, Preschool | 2 | 2024 | 12011 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 1996 | 76 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2000 | 583 | 0.030 |
Why?
| | Air Pollution | 1 | 1999 | 315 | 0.030 |
Why?
| | Task Performance and Analysis | 1 | 2017 | 203 | 0.030 |
Why?
| | Diet | 1 | 2023 | 1282 | 0.030 |
Why?
| | Fungal Proteins | 1 | 1996 | 143 | 0.030 |
Why?
| | Amygdala | 1 | 2017 | 203 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2016 | 2131 | 0.030 |
Why?
| | Wounds, Gunshot | 1 | 2019 | 260 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2016 | 66 | 0.030 |
Why?
| | Psychological Tests | 1 | 2016 | 131 | 0.030 |
Why?
| | Clone Cells | 1 | 2016 | 263 | 0.030 |
Why?
| | Personal Construct Theory | 1 | 2015 | 5 | 0.030 |
Why?
| | Nevirapine | 1 | 2015 | 18 | 0.030 |
Why?
| | Affect | 1 | 2018 | 323 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 1999 | 568 | 0.030 |
Why?
| | Zidovudine | 1 | 2015 | 77 | 0.030 |
Why?
| | Lamivudine | 1 | 2015 | 65 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 951 | 0.030 |
Why?
| | Gene Expression | 1 | 2000 | 1481 | 0.030 |
Why?
| | Reward | 1 | 2017 | 248 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 43 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 219 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2015 | 282 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 210 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 165 | 0.030 |
Why?
| | Molecular Chaperones | 1 | 1996 | 199 | 0.030 |
Why?
| | Teaching Materials | 1 | 1994 | 22 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 154 | 0.030 |
Why?
| | Nursing Evaluation Research | 1 | 1994 | 43 | 0.030 |
Why?
| | Hospital Units | 1 | 2014 | 32 | 0.030 |
Why?
| | Demography | 1 | 2015 | 283 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2024 | 1798 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 344 | 0.020 |
Why?
| | Research Design | 1 | 2020 | 1155 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2022 | 1174 | 0.020 |
Why?
| | Anemia | 1 | 2015 | 192 | 0.020 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 131 | 0.020 |
Why?
| | Lipolysis | 1 | 2013 | 44 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2015 | 207 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1940 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2014 | 232 | 0.020 |
Why?
| | Patient Care Planning | 1 | 1994 | 171 | 0.020 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 2017 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2013 | 199 | 0.020 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2013 | 154 | 0.020 |
Why?
| | Air Pollutants | 1 | 1997 | 407 | 0.020 |
Why?
| | Adolescent Health Services | 1 | 2013 | 74 | 0.020 |
Why?
| | Curriculum | 1 | 2020 | 1083 | 0.020 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1996 | 416 | 0.020 |
Why?
| | Pregnancy | 2 | 2016 | 7276 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 539 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 1996 | 585 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2012 | 284 | 0.020 |
Why?
| | Aggression | 1 | 2012 | 180 | 0.020 |
Why?
| | Triglycerides | 1 | 2013 | 529 | 0.020 |
Why?
| | Lung Diseases | 1 | 1997 | 787 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1518 | 0.020 |
Why?
| | Mitochondria | 1 | 1996 | 1000 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 663 | 0.020 |
Why?
| | Vital Capacity | 2 | 2000 | 293 | 0.020 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2007 | 43 | 0.020 |
Why?
| | Forced Expiratory Volume | 2 | 2000 | 451 | 0.020 |
Why?
| | Receptors, CCR5 | 1 | 2007 | 60 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2007 | 120 | 0.020 |
Why?
| | Lung | 1 | 2000 | 4141 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 5 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2007 | 365 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2008 | 279 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2007 | 325 | 0.010 |
Why?
| | Deer | 1 | 2006 | 52 | 0.010 |
Why?
| | Viral Load | 1 | 2007 | 528 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 409 | 0.010 |
Why?
| | Immune Sera | 1 | 1984 | 77 | 0.010 |
Why?
| | Ovulation | 1 | 1984 | 46 | 0.010 |
Why?
| | Body Mass Index | 1 | 2013 | 2466 | 0.010 |
Why?
| | Acute Disease | 1 | 2007 | 1049 | 0.010 |
Why?
| | Immunization, Passive | 1 | 1984 | 90 | 0.010 |
Why?
| | HLA-A3 Antigen | 1 | 2003 | 6 | 0.010 |
Why?
| | HLA-B7 Antigen | 1 | 2003 | 7 | 0.010 |
Why?
| | HLA-A2 Antigen | 1 | 2003 | 36 | 0.010 |
Why?
| | Superantigens | 1 | 2003 | 70 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 2003 | 123 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 138 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2007 | 1172 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2007 | 1140 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2006 | 514 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 219 | 0.010 |
Why?
| | Gonadal Steroid Hormones | 1 | 1984 | 143 | 0.010 |
Why?
| | Basal Metabolism | 1 | 2003 | 58 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2003 | 196 | 0.010 |
Why?
| | Blood Glucose | 1 | 2013 | 2359 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1730 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 849 | 0.010 |
Why?
| | Brain | 1 | 2014 | 3009 | 0.010 |
Why?
| | Minnesota | 1 | 2001 | 168 | 0.010 |
Why?
| | Inflammation | 2 | 2006 | 2921 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2003 | 590 | 0.010 |
Why?
| | Nasal Lavage Fluid | 1 | 1999 | 15 | 0.010 |
Why?
| | Eosinophil Granule Proteins | 1 | 1999 | 15 | 0.010 |
Why?
| | Body Composition | 1 | 2003 | 689 | 0.010 |
Why?
| | Albumins | 1 | 1999 | 119 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1999 | 319 | 0.010 |
Why?
| | Nasal Mucosa | 1 | 1999 | 113 | 0.010 |
Why?
| | Interleukins | 1 | 2000 | 248 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2003 | 2197 | 0.010 |
Why?
| | Biomarkers | 2 | 2000 | 4354 | 0.010 |
Why?
| | Leukocytes | 1 | 1999 | 301 | 0.010 |
Why?
| | Blood Proteins | 1 | 1999 | 239 | 0.010 |
Why?
| | Eosinophils | 1 | 1999 | 319 | 0.010 |
Why?
| | Urban Health | 1 | 1997 | 96 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2000 | 1046 | 0.010 |
Why?
| | Suppression, Genetic | 1 | 1996 | 25 | 0.010 |
Why?
| | Genes, Fungal | 1 | 1996 | 55 | 0.010 |
Why?
| | DNA, Fungal | 1 | 1996 | 78 | 0.010 |
Why?
| | Protein Precursors | 1 | 1996 | 136 | 0.010 |
Why?
| | Biological Transport | 1 | 1996 | 425 | 0.010 |
Why?
| | DNA, Mitochondrial | 1 | 1996 | 212 | 0.010 |
Why?
| | Cold Temperature | 1 | 1996 | 207 | 0.010 |
Why?
| | Linear Models | 1 | 1997 | 852 | 0.010 |
Why?
| | Mitochondrial Proteins | 1 | 1996 | 264 | 0.010 |
Why?
| | Animals | 3 | 2006 | 38416 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 669 | 0.010 |
Why?
| | Base Sequence | 1 | 1996 | 2175 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1996 | 2134 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1996 | 2886 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2000 | 2812 | 0.010 |
Why?
| | Students | 1 | 1997 | 658 | 0.010 |
Why?
| | Phenotype | 1 | 1996 | 3216 | 0.000 |
Why?
| | Mice | 1 | 2003 | 18493 | 0.000 |
Why?
| | Androstenedione | 1 | 1984 | 10 | 0.000 |
Why?
| | Estrone | 1 | 1984 | 41 | 0.000 |
Why?
| | Sheep | 1 | 1984 | 879 | 0.000 |
Why?
| | Estradiol | 1 | 1984 | 515 | 0.000 |
Why?
|
|
Forster's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|